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Chicago, IllinoisOBJECTIVES This study sought to: 1) determine the feasibility of using 3-dimensional transthoracic
echocardiography (3D TTE) in patients with implantable cardiac resynchronization devices, pacemakers,
and deﬁbrillators to visualize the device leads in the right heart and their position relative to the tricuspid
valve leaﬂets; 2) determine the prevalence of different lead positions; and 3) study the relationship
between lead location and tricuspid regurgitation (TR) severity.
BACKGROUND Pacemaker, deﬁbrillator, and cardiac resynchronization device implantation is
currently guided by ﬂuoroscopy, not allowing targeted lead positioning relative to the tricuspid valve leaf-
lets. These leads have been reported to cause TR of variable degrees, but echocardiography is not routinely
used to elucidate the mechanisms of lead interference with tricuspid valve leaﬂets in individual patients.
METHODS 3D TTE full-volume images of the right ventricle and/or zoomed images of the tricuspid
valve were obtained in 121 patients with implanted devices. Images were viewed ofﬂine to determine
the position of the device-lead relative to the tricuspid valve leaﬂets. Severity of TR was estimated on
the basis of vena contracta measurements.
RESULTS 3D TTE clearly depicted lead position in 90% of patients. The right ventricular lead was
impinging on either the posterior (20%) or septal (23%) leaﬂet or was not interfering with leaﬂet motion
(53%) when positioned near the posteroseptal commissure or in the central portion of the tricuspid valve
oriﬁce. In the remaining patients, leads were impinging on the anterior leaﬂet (4%) or positioned in either
the anteroposterior or anteroseptal commissure (3%). Leads interfering with normal leaﬂet mobility were
associated with more TR than nonimpinging leads (vena contracta: median 0.62 cm [1st and 3rd quar-
tiles: 0.51, 0.84 cm] vs. 0.27 cm [1st and 3rd quartiles: 0.00, 0.48 cm]; p < 0.001).
CONCLUSIONS 3D TTE showed a clear association between device lead position and TR. To minimize
TR induced by device-leads, 3D TTE guidance should be considered for placement in a commissural
position. (J Am Coll Cardiol Img 2014;7:337–47) ª 2014 by the American College of Cardiology
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PA B B R E V I A T I O N S
A N D A C R O N YM S
A = anterior
AP = anteroposterior
AS = anteroseptal
ICD = implantable cardiove
deﬁbrillator
M = middle or central locat
implantable device lead
P = posterior
PS = posteroseptal
S = septal
3D TTE = 3-dimensional
transthoracic echocardiogr
TR = tricuspid regurgitatio
2D TTE = 2-dimensional
transthoracic echocardiogr
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338ermanent pacemaker, implantable cardioverter-
deﬁbrillator (ICD), and cardiac resynchroni-
zation device implantations are growing
steadily as life expectancy of the population
increases and indications for these devices expand.
The association between permanent pacemaker,
ICD, or cardiac resynchronization device leads
and tricuspid regurgitation (TR) has not been
well-described. Published data on the frequency of
device-related TR are conﬂicting, with reported
incidence ranging anywhere between 7% and 39%See page 348(1). Much of the available data originates from au-
topsy reports and surgical case series, where the
mechanism of device-related TR was determined inrter-
ion of
aphy
n
aphya “non-beating” heart (1–4). To date, there
is no reliable imaging technique to assess
device-lead–related interference with the
tricuspid valve.
Tricuspid regurgitation is not a benign
condition.Althoughgenerallywell-tolerated
in its early stages, with time, TR might
lead to pulmonary hypertension, right sided
heart failure, and increased morbidity. A
recent study indicates that more than mod-
erate TR is associated with reduced 1-year
survival (65% to 80%) (5). Therefore, it
would be beneﬁcial to be able to identify
device-lead interference with normal tri-
cuspid valve leaﬂet mobility leading to TR.
Two-dimensional (2D) transthoracic
echocardiography (TTE) can only visu-
alize device leads crossing the tricuspidvalve in 12% to 17% (4,6) of patients, making it an
unreliable technique to assess device-lead related
TR. Prior 2D TTE studies focused on demon-
strating worsening TR severity after device-lead
implantation (7–9). None of these studies, howev-
er, were able to clearly describe the mechanism by
which the device-lead resulted in TR worsening.
Three-dimensional (3D) TEE allows detailed en-
face visualization of the tricuspid valve anatomy from
both the atrial and ventricular perspectives, including
simultaneous visualization of all 3 tricuspid valve
leaﬂets. Accordingly, we hypothesized that 3D TTE
datasets would be able to depict the course and po-
sition of the device-lead as it traverses the tricuspid
valve and determine the mechanism of device-lead
induced TR, when present.
The aims of this study were to determine: 1) the
feasibility of 3D TTE imaging of the tricuspid valveand right ventricular device-lead as it traverses the
valve; 2) the prevalence of different lead positions
with respect to tricuspid valve leaﬂets and com-
missures; and 3) the mechanism and relationship
between lead position and TR severity.
METHODS
Patient population. We identiﬁed 135 consecutive
patients from our echocardiography database with
permanent pacemaker, ICD, or cardiac resynchro-
nization device therapy who had undergone com-
plete 2D and 3D TTE imaging of the tricuspid
valve with the device lead in situ between January
2010 and April 2013. All patients had 3D TTE
studies including a full volume and/or zoomed
acquisition of the tricuspid valve. Care was taken
during ofﬂine analysis to optimally depict the course
of the device lead at the level of the tricuspid valve
leaﬂets, resulting in exclusion of 14 of 135 patients
due to inadequate image quality (10%). Therefore,
121 patients were included in the study (64 male
and 57 female; mean age 65  15 years, range 28
to 104 years). Of the 121 patients, 62 also had pre-
implantation 2D echocardiograms. Of these, 9 did
not have adequate imaging of the tricuspid valve;
thus 53 of the study patients (24 male and 29
female; mean age 65  15 years, range 31 to 93
years) who had pre-implantation echocardiograms
were included.
Demographic information, site of device gener-
ator implantation (left vs. right chest pocket), and
type of device placed (permanent pacemaker, ICD,
or cardiac resynchronization device) were obtained
from a chart review. This study was approved by the
institutional review board.
2D TEE. Comprehensive 2D and color Doppler
evaluation was performed by an experienced so-
nographer with the iE33 imaging system equipped
with an S5 transducer (Philips Healthcare, And-
over, Massachusetts). Digital loops were stored
and analyzed ofﬂine (Xcelera Workstation, Philips
Healthcare). Quantiﬁcation of TR was achieved by
measuring the largest vena contracta in centimeters
from either the right ventricular inﬂow view or the
apical 4-chamber view, following published guide-
lines (10) (Fig. 1). Vena contracta measurements
were similarly performed on the 53 available pre-
implantation echocardiograms. Pre- and post-
implantation vena contracta were compared between
the group classiﬁed as impinging and the group
designated nonimpinging (see the following device-
lead position assessment section for details). Peak
TR gradient was measured with the modiﬁed
Figure 1. Vena Contracta Measurement
Two-dimensional color Doppler images of a patient with tricuspid regurgitation
and device-lead in situ, showing vena contracta measurement (between the
yellow arrows) from the right ventricular (RV) inﬂow view (left) and apical
4-chamber (4-CH) view (right). PM ¼ pacemaker wire.
Figure 2. Device-Lead Positions and Percentage of Leads
Located in Each Position
Device-lead positions (left) and percentage of leads (of a total of 121 patients
studied) located in each position (right). A ¼ anterior leaﬂet impingement;
AP ¼ device-lead in the anteroposterior commissure; AS ¼ device-lead in the
anteroseptal commissure; M ¼ device lead in the center of the tricuspid valve
oriﬁce; P ¼ posterior leaﬂet impingement; PS ¼ device-lead in the poster-
oseptal commissure; S ¼ septal leaﬂet impingement.
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339Bernouli equation, incorporating the maximum TR
jet velocity.
3D TEE. The 3D TTE studies were performed with
a Phillips iE33 ultrasound system (Philips Health-
care) with a fully sampled matrix-array transducer
(model X7-2t). The tricuspid valve was imaged
from the apical 4-chamber view with full volume
and/or 3D zoom modes. The full volume imaging
was performed in the right ventricle-focused view,
wherein the central axis of the pyramidal scan vol-
ume was aligned with the right ventricle long axis.
Image acquisition was performed with electrocar-
diographic gating over 4 consecutive cardiac cycles
during a single breath-hold (11). For the zoom
mode acquisitions, biplane imaging was initially
performed to ensure that the entire tricuspid valve
was captured. In the zoom mode, the box height
and width were optimized to enclose a section of the
right ventricle and right atrium together with the
full width of the valve within the scan volume. After
the gain was optimized, the image was cropped and
oriented to visualize the tricuspid valve in the en face
view (right ventricular or right atrial perspective),
depending on which orientation best depicted the
device-lead. The tricuspid valve was oriented with
the septum in the 6-o’clock position in accordance
with American Society of Echocardiography
guidelines (Fig. 2) (11).
Device lead position assessment. The 3D images
were cropped (QLAB 9.0, Phillips Healthcare) and
displayed to enable identiﬁcation of the device-lead
position at the level of the tricuspid annulus. The
device lead was described as impinging on either
the anterior (A), posterior (P), or septal (S) leaﬂets
if it was seen interfering with leaﬂet motion (Fig. 2,
left panel). If the device-lead was in the commis-
sure, the lead position was named according to
the commissural location between the respective
2 tricuspid leaﬂets (i.e., anteroseptal [AS], antero-
posterior [AP], and posteroseptal [PS]). Finally,
the position was noted as mobile (M) when the
lead was seen traversing the tricuspid valve in the
middle without interfering with valvular function.
The 3D images alone were used to make the
assessment, and corroboration was not sought from
2D imaging.
Device pulse generator position was recorded as
“left chest” or “right chest” or “both” if 2 pockets had
been constructed and leads from the ﬁrst pulse
generator were left in the heart. Device pulse
generator position was assessed on the chest x-ray
taken closest to the time of 3D TTE.
Inter-reader agreement analysis. A randomly
selected group of 32 patients was used to assessthe inter-reader agreement in the evaluation of
lead position. Determinations of 2 experienced
independent observers were compared with each
other by calculating the rate of agreement.
A randomly selected group of 50 patients was
used to assess the inter-reader agreement in the
evaluation of TR. Two experienced independent
observers performed vena contracta measurements,
while being blinded to the results of each other.
Measured vena contracta values were used to clas-
sify TR severity as “mild,” “moderate,” or “severe,”
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gitation (10). Inter-reader agreement in this clas-
siﬁcation was assessed with kappa statistics.
The calculated kappa coefﬁcients were judged as
follows: 0.0 to 0.2 low, 0.21 to 0.4 moderate, 0.41
to 0.6 substantial, 0.61 to 0.8 good, and >0.8
excellent.
Statistical analysis. Continuous variables were
expressed with mean  SD or medians (with
1st and 3rd quartiles) for variables that did not
follow a normal distribution, according to the
Kolmogorov-Smirnov test. Mann-Whitney U test
was used to make comparisons between indepen-
dent groups, and Wilcoxon rank paired test was
used to compare related samples (namely between
pre– and post–device-lead insertion vena contracta
values). Independent samples Kruskal-Wallis test
was used to determine whether differences existed
between data in more than 2 groups. Categorical
variables such as prevalence of different lead
positions were expressed in percentage, and dif-
ferences were tested with chi-square statistics.
A p value <0.05 was considered statistically
signiﬁcant.
RESULTS
3D TTE was feasible in 121 of 135 patients (90%).
Of the 121 patients studied, 63 (52%) had ICDs,
30 (25%) had cardiac resynchronization devices, and
27 (22%) had permanent pacemaker leads. Most
patients had device implantation from a left-sided
chest pocket (n ¼ 97, 80%), whereas only 13 pa-
tients (11%) had implantation from a right-sided
pocket. Seven patients had 2 leads in the right
ventricle. See Table 1 for a summary of baseline
characteristics.
Pacemaker leads were best evaluated from the
right ventricle perspective in both the zoomed and
full volume acquisitions. Fifty-six patients (46%)
showed device-lead impingement against 1 of the
leaﬂets; S leaﬂet motion was restricted in 28 pati-
ents (23%) (Online Videos 4 and 6), the P leaﬂet
in 24 patients (20%) (Online Video 3), and the A
leaﬂet in 5 patients (4%) (Online Videos 5 and 7)
(Fig. 2, right panel). In the remaining 65 patients
(54%) the device lead was located either in a
commissure (n ¼ 35, 29%) (Online Videos 1 and 2)
or in the middle of the tricuspid oriﬁce M (n ¼ 28,
23%). When the lead was either in a commissure or
in the middle of the tricuspid valve oriﬁce, the
device-lead did not seem to restrict leaﬂet mobility,
because the leaﬂets were noted to move freely
around the lead. In the commissural position, mostof the leads were seen in the PS commissure (n ¼
32, 26%). Only 3 leads were found in the AS
commissure (2%), and only 1 was found in the AP
commissure (1%) (Fig. 3, Table 2). Two inde-
pendent observers agreed on device-lead location
in 27 of 32 cases (84%). Disagreements were be-
tween S versus PS position (4 cases) and PS versus
P position (1 case).
The TR associated with device-lead impinge-
ment (A, S, or P) was signiﬁcantly more severe
compared with that associated with a lead located in
the center of the oriﬁce (M) or in a commissural
position (AP, AS, PS) (vena contracta 0.62 cm
[1st and 3rd quartiles: 0.51, 0.84 cm] vs. 0.27 cm
[1st and 3rd quartiles: 0.00, 0.48 cm]; p < 0.001)
(Figs. 3 to 5). In patients with severe TR (vena
contracta $0.7 cm, n ¼ 26), most (22 of 26, 85%)
had device leads impinging on a leaﬂet (A, S, or P).
The calculated kappa coefﬁcient for vena contracta
measurement was 0.70, signifying good agreement
between the 2 independent observers. The peak
TR gradient associated with an impinging device-
lead (A, S, or P) was higher than the peak TR
gradient associated with a non-impinging device-
lead (located in the M, AP, AS, or PS position)
(peak TR gradient 35 mm Hg [1st and 3rd quar-
tiles: 26, 41 mm Hg] vs. 29 mm Hg [1st and 3rd
quartiles: 23, 37 mm Hg]; p ¼ 0.04).
In the subset of patients with pre- and post-lead
implantation 3D echocardiograms (n ¼ 53, 44%),
a signiﬁcant increase in TR severity was noted
after device-lead implantation in those with leads
noted to be impinging on the A, S, or P tricuspid
leaﬂets (vena contracta: 0.00 cm [1st and 3rd
quartiles: 0.00, 0.59 cm] pre-implantation vs. 0.62
cm [1st and 3rd quartiles: 0.47, 0.74 cm] post-
implantation; p < 0.01). In contrast, in patients
with nonimpinging device-leads, no signiﬁcant
worsening in TR was noted (vena contracta: 0.00
cm [1st and 3rd quartiles: 0.00, 0.43 cm] pre-
implantation vs. 0.30 cm [1st and 3rd quartiles:
0.00, 0.51 cm] post-implantation; p ¼ 0.52)
(Fig. 6). In all cases with 2 device-leads (n ¼ 7), 1
lead was noted to be impinging. Therefore, these
cases were included in the group with the
impinged leaﬂet.
Device pulse generator position (left or right
chest) was not associated with a difference in TR
(vena contracta left-sided implantation [n ¼ 97]
0.48 cm [1st and 3rd quartiles: 0.00, 0.68 cm]
vs. right-sided implantation [n ¼ 13] 0.56 cm
[1st and 3rd quartiles: 0.00, 0.49 cm], p ¼ 0.21).
Device type (i.e., pacemaker, ICD, or biven-
tricular ICD) did not have any impact on the
Table 1. Baseline Characteristics of Study Subjects and Subgroup With Pre– and Post–Device-Lead Implantation
3D Echocardiography
Total Population
(n [ 121)
Pre-/Post-Implantation Echo
(n [ 53)
Age, yrs 65  15 (28–104) 65  15 (31–93)
Male 64 (53) 24 (45)
Peak TR gradient, mm Hg 33  12 (103) 34  11 (45)
Interval between device
implantation and 3D echo, yrs
3.9  3.9 (80) 3.9  4.3 (50)
Interval between pre- and
post-implantation 3D echo, yrs
d 3.8  3 (53)
Device data
With ICD 63 (52) 26 (49)
With PPM 27 (22) 9 (17)
With BIV ICD 30 (25) 18 (34)
Unknown device type 1 (1) 0 (0)
Left-sided implantation 97 (80) 45 (85)
Right-sided implantation 13 (11) 8 (15)
Unknown implantation site 10 (8) 0 (0)
Leads from both right and left 1 (1) 0 (0)
Patients with 2 wires in situ 7 (6) 0 (0)
Values are mean  SD (range), n (%), or mean  SD (n).
BIV ¼ biventricular; echo ¼ echocardiogram; ICD ¼ implantable cardioverter-deﬁbrillator; PPM permanent pacemaker; 3D ¼ 3-dimensional; TR ¼ tricuspid
regurgitation.
Figure 3. Device Lead Locations on 3D Transthoracic Echocardiography
(A) Three-dimensional (3D) zoom examples of nonimpinging leads. From left-to-right: device-leads are found in the PS commissure (Online
Video 1), AP commissure (Online Video 2), M, and AS. (B) 3D zoom examples of impinging leads. From left-to-right: device-leads are found
against the P (Online Video 3), S (Online Video 4), and A (Online Video 5). All these positions were associated with interference of leaﬂet
motion (Online Videos 1, 2, 3, 4, and 5). Arrows point to the device-lead. Abbreviations as in Figure 2.
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Table 2. Device Lead Position and Related Characteristics
Device Lead Positions
A
(n [ 5)
P
(n [ 24)
S
(n [ 28)
PS
(n [ 32)
AP
(n [ 1)
AS
(n [ 3)
M
(n [ 28)
VC
(cm)
Device type*
ICD (n ¼ 63) 3 10 13 27 0 2 15 0.46 [0.00, 0.63]
PPM (n ¼ 27) 2 5 7 5 1 1 6 0.51 [0.00, 0.70]
BIV ICD (n ¼ 30) 2 9 8 5 0 0 6 0.53 [0.07, 0.64]
Post-implantation sitey
Left (n ¼ 97) 3 19 26 27 1 3 18 0.50 [0.00, 0.58]
Right (n ¼ 13) 1 3 1 3 0 0 5 0.56 [0.49, 0.72]
No data (n ¼ 10) 1 2 1 2 0 0 4 0.15 [0.00, 0.49]
Pre-implantation tricuspid regurgitation VC, cm
VC (n ¼ 53) 0.62 d 0.59 [0.47, 0.64] 0.72 [0.48, 0.77] 0.24 [0.00, 0.45] d 0.00 0.39 [0.00, 0.63] 0.46 [0.00, 0.63]
1 9 11 17 d 2 13 53
Post-implantation tricuspid regurgitation VC, cm
VC (n ¼ 121) 0.62 [0.57, 0.72] 0.61 [0.53, 0.78] 0.65 [0.48, 0.85] 0.12 [0.00, 0.44] 0.41 d 0.00 [0.00, 0.25] 0.33 [0.00, 0.51] 0.49 [0.00, 0.66]
Values are n or median [1st and 3rd quartiles]. *One patient did not have any records of device type. yOne patient had device-leads coming from both left and right chest pockets;
this patient was not included in the table.
A ¼ anterior impingement; AP ¼ anteroposterior commissure; AS anteroseptal commissure; M ¼ center of the valve; P ¼ posterior impingement; S ¼ septal impingement; PPM
permanent pacemaker; PS ¼ posteroseptal commissure; VC ¼ vena contracta; other abbreviations as in Table 1.
Figure 4.
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342severity of TR. Median vena contracta for the group
that received ICD versus pacemaker versus the
cardiac resynchronization device therapy was 0.46
[1st and 3rd quartiles: 0.00, 0.63], 0.51 [1st and 3rdCase of Septal Impingement by a Device-Lead
med image (bottom, left) showing impingement of septal leaﬂet,
ding 2-dimensional color (RV inﬂow, top left and apical 4-chamber,
wing severe tricuspid regurgitation. White arrow points at the
d. See also the corresponding video of this case (Online Video 6).
ions as in Figures 1 and 3.quartiles: 0.00, 0.70], and 0.55 [1st and 3rd quar-
tiles: 0.07, 0.64], respectively. Even with non-
impinging leads excluded (i.e., leads in the AS,
AP, PS, or M position), the group that received
ICDs (biventricular ICD or ICD only, n ¼ 43,
vena contracta 0.61 cm [1st and 3rd quartiles: 0.51,
0.81 cm]) did not show signiﬁcantly different TR
severity than those who received pacemakers
(n ¼ 14, vena contracta 0.68 cm [1st and 3rd
quartiles: 0.58, 0.82 cm]).
The date of device-lead implantation was avail-
able in 80 of 121 (66%) patients. Interval between
device-lead implantation and the 3D TTE was not
longer in patients with impinging leads (A, S, or P)
when compared with patients with nonimpinging
leads (M, AP, AS, or PS positions; 3.4 years [1st
and 3rd quartiles: 1.5, 5.9 years] vs. 2.6 years [1st
and 3rd quartiles: 1.0, 5.1 years]; p ¼ 0.33).
Furthermore, the correlation between the age of the
device-lead (number of years between lead place-
ment and 3D TTE) was poor (r ¼ 0.06, p <
0.00001), suggesting that TR severity was not
associated with older device-leads.
In most cases, device-related TR was secondary
to lead adherence to or impingement on a leaﬂet,
resulting in impaired leaﬂet mobility. Perforation
was identiﬁed in 2 cases; malcoaptation was
identiﬁed in 3 cases (Online Video 8). In 7 patients
with 2 leads present, 1 of 2 leads was felt to be
impinging upon a leaﬂet, interfering with leaﬂet
Figure 5. Case of Device-Lead in a Commissural Position
A 3D zoomed image (bottom, left) showing device-lead in the posteroseptal
commissure and corresponding 2-dimensional color (RV inﬂow, top left and
apical 4-chamber, right) showing trace tricuspid regurgitation. Arrows point at
the device-lead. See also the corresponding video of this case (Online Video 1).
Abbreviations as in Figures 1 and 3.
J A C C : C A R D I O V A S C U L A R I M A G I N G , V O L . 7 , N O . 4 , 2 0 1 4 Mediratta et al.
A P R I L 2 0 1 4 : 3 3 7 – 4 7 Tricuspid Regurgitation by Implantable Devices
343mobility. Average vena contracta in tricuspid valves
with 2 leads was 0.56  0.26 cm (range 0.20 to
0.95 cm). Examples of mechanisms of TR as seen
on 3D echocardiographic images are depicted in
Figures 7 and 8.
D I SCUSS ION
This study conﬁrmed that 3D TTE is feasible for
the visualization of device-lead position in the
tricuspid valve in most patients. Leads positioned
against tricuspid leaﬂets impinge upon or restrict
leaﬂet motion, resulting in a greater severity of TR,
compared with leads positioned within 1 of the
commissures or leads that remain mobile as they
cross the tricuspid valve through its center. In the
subset of patients who had pre- and post-device
implantation images, an increase in TR severity
was noted selectively in patients with leads
impinging on the leaﬂets.
Device-lead placement techniques and the tricuspid
valve. Placement of ICDs, permanent pacemaker,
and biventricular devices is performed under ﬂuo-
roscopic guidance with the aim of directing the tip
of the lead most commonly to the right ventricle
apex, the interventricular septum, or the right
ventricle outﬂow tract. Determining the lead posi-
tion at the level of the tricuspid valve annulus with
respect to the leaﬂets is difﬁcult, because tricuspid
valve leaﬂets are not seen on ﬂuoroscopy. Right
ventricle lead placement techniques vary, depending
on the operator and the center where the procedure
is performed. In general, 1 of 3 different techniques
is used: 1) prolapsing the lead across the tricuspid
valve by ﬁrst looping it in the right atrium, then
pushing the loop forward with the inner stylet until
it falls through the valve; 2) crossing the valve
directly, aimed toward the target location with a
shaped stylet in place; or 3) crossing the valve
directly toward the right ventricle outﬂow tract with
a curved stylet in place, then retracting the lead until
it is aimed at the target location (12). As shown in
our study, device-lead placement results in a variety
of lead locations at the level of the tricuspid valve
annulus. Although in this study it was not possible
to determine whether individual procedural tech-
nique resulted in preferential lead positions that are
associated with less severe TR, this remains to be
determined in future studies.
TR in the presence of device-leads. Previous studies
have reported a prevalence of device-lead related TR
ranging from 7% to 39% (1). This wide range is
likely attributable to multiple factors. First, device-
lead associated TR is difﬁcult to evaluate in abeating heart. So far, there has been no reliable
method to assess the position of a device-lead as it
crosses the tricuspid valve. Most of the current in-
formation was obtained from autopsy reports and
surgical case series (2–4,13–15). Moreover, initial
studies using 2D echocardiography described con-
ﬂicting ﬁndings with regard to the association
between severity of TR and the presence of a
device-lead (1). Whereas early animal studies and
prospective human studies showed no signiﬁcant
difference in TR severity pre- and post-endocardial
lead implantation (16–18), later studies suggested
an increase in TR severity after device implantation
(8,19,20). These conﬂicting observations probably
originate from the fact that, with 2D TTE, device-
leads are fully visualized as they traverse the
tricuspid valve annulus in only 15% of cases (1,6).
Indeed, the tricuspid valve is difﬁcult to assess with
2D TTE, because of the anterior position of this
valve, its non-planar shape (21), and the complex
geometry of the right ventricle. Accordingly, 2D
echocardiography does not seem to provide sufﬁ-
cient information to assess the mechanism of TR
in patients with device-leads. In contrast, 3D TTE
takes advantage of the anterior position of the
tricuspid valve, allowing en face visualization of the
Figure 6. Patients With Pre– and Post–Device-Lead
Implantation Echocardiograms
Pre- and post-implantation tricuspid regurgitation severity (as measured by
vena contracta) for patients with impinging device-leads (A, S, P) and patients
with nonimpinging device-leads (AS, AP, PS, M). Pre-implantation data (n ¼ 53)
correspond with pink bars, whereas post-implantation data (n ¼ 121) corre-
spond with blue bars. Post-implantation tricuspid regurgitation was signiﬁ-
cantly more severe in patients with impinging leads (*p < 0.05) than in patients
with nonimpinging leads. The n values on the bar graphs represent the
number of patients in the corresponding groups. Abbreviations as in Figure 2.
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344tricuspid valve from both the atrial or ventricular
perspective and easy, simultaneous identiﬁcation of
all leaﬂets and commissures. In addition, the course
of the device-lead as it traverses the tricuspid
annulus is easily appreciated (11,22–24). It has been
previously reported that 3D TTE images of theCase of Lead Adherence
sional zoomed image of tricuspid valve demonstrating 2 leads
with the top lead adherent to the anterior leaﬂet. This patient had
ptomatic tricuspid regurgitation and was taken to the operating
lead removal. Note that the lead is adhering to the anterior leaﬂet
uspid valve (see surgical photo on the rightdarrows point at the
p lead is adherent). See accompanying Online Video 7.tricuspid valve can be acquired in 90% of patients
who have adequate 2D images (25). We demon-
strated that with 3D TTE it was feasible to
consistently and simultaneously image the 3
tricuspid valve leaﬂets. Furthermore, the 3D data-
sets were of sufﬁcient quality to allow multiplanar
reconstruction and ofﬂine cropping to facilitate
visualization of the device-lead at the level of the
tricuspid annulus and its anatomic relationship with
the leaﬂets.
To our knowledge, only 1 other study has used
3D TTE to evaluate device-lead location and its
association with TR (6). Similar to our study, Seo
et al. (6) found that 3D TTE was useful to follow
the course and position of the lead as it traverses
the tricuspid annulus and that device-lead location
in a commissural position was associated with less
severe TR. However, in their study, the number of
patients with signiﬁcant TR was much lower.
Accordingly, we were able to draw stronger con-
clusions with regard to the association between
device-lead position and signiﬁcant TR. In addi-
tion, the method used to quantify TR severity in
their study was the ratio of TR area to right atrial
area, which has several limitations. In contrast, we
used the vena contracta of the TR jet, because it is
simple, reproducible, has been previously vali-
dated, and seems to be equally useful with both
central and eccentric jets with a sensitivity and
speciﬁcity of 89% and 93%, respectively, in
identifying severe TR (26). In addition, the vena
contracta has been shown to be superior to jet area
and the ratio of jet area to right atrial area,
correlating more closely with the effective regur-
gitant oriﬁce (27). We were also able to show that
impinging device-leads were associated with a
higher peak TR gradient (used in this study as a
surrogate marker for pulmonary arterial hyper-
tension) than nonimpinging device-leads. This
association might simply reﬂect that impinging
device-leads are associated with more TR or that
worsening pulmonary hypertension (if not related
to the presence of TR) might have a tendency to
guide the lead into a noncommissural position.
This association requires further study.
Mechanism of device-lead induced TR. A number of
mechanisms have been proposed to explain device-
lead associated TR, including leaﬂet perforation
(4), mechanical interference of the lead with
the leaﬂets, leading to incomplete closure or mal-
coaptation (4,8), entanglement of the lead within the
tricuspid valve chordal apparatus (4,28), adherence
of the lead to a leaﬂet (4), and delayed right ventricle
activation or alteration in right ventricle geometry
Figure 8. Case of Tricuspid Valve Malcoaptation
A 3D zoomed image of the tricuspid valve from the RV perspective illustrating
malcoaptation (*) of the leaﬂets with device-lead in situ (white arrow, far
right). Corresponding 2-dimensional color Doppler images show presence of
severe tricuspid regurgitation. Arrows point at the device-leads. See also
accompanying Online Video 8. Abbreviations as in Figures 1 and 3.
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345during pacing (29). Most of these observations have
originated from autopsy or operative reports.
The usefulness of 3D TTE to elucidate the
mechanism of device-lead associated tricuspid valve
interference was ﬁrst described in 2007 (30) when
ﬁndings on 3D TTE suggestive of leaﬂet impinge-
ment were conﬁrmed by surgical ﬁndings. With
3D TTE, we were able to observe both normal
leaﬂet mobility and restricted leaﬂet motion due to
a device-lead impingement, with the septal leaﬂet
being the most commonly affected. In the subset of
patients who had pre-implantation echocardiograms
of satisfactory quality to allow vena contracta mea-
surements, we were able to conﬁrm that device-leads
impinging on a leaﬂet worsened TR severity post-
implantation.
In our study group, we were also able to clearly
identify the following mechanisms: leaﬂet perfora-
tion, leaﬂet malcoaptation, and presence of multiple
device leads. Most of the interfering leads were noted
to be adhering to or impinging upon a leaﬂet and
impairing leaﬂet coaptation (Figs. 3, 7, and 8).
Therefore, 3D TTE studies should focus on deter-
mining whether a device-lead is freely mobile, located
in a commissural position, or restricting leaﬂet mo-
tion. If the device-lead is felt to be restricting leaﬂet
motion, further imaging or ofﬂine cropping of the
3D dataset should be performed to determine the
mechanism causing TR, if possible (Table 3).
One would expect that the older the device-lead
the greater the likelihood of impingement, adher-
ence, and therefore worsening TR; however, in our
population, the age of the device-lead did not seem
to have an obvious impact on TR severity or like-
lihood of leaﬂet impingement. We were able to
accumulate information on implantation dates in
only 66% of our patients, so it is possible that thisTable 3. 3D Transthoracic Imaging in Patients With a Pacemaker, I
Transducer Position Structures
Apical 4-chamber Tricuspid valve and pacemaker lead Biplane i
3D zoo
Crop a
follow
Right ventricle and pacemaker lead Full-volu
decrea
view t
walls o
Tilt py
plane
referen
to the
device
positio
CRT ¼ cardiac resynchronization therapy; 3D ¼ 3-dimensional; other abbreviationinformation is limited; however, these results might
suggest that correction of the device-lead associated
TR might lie in the method of lead placement or
ﬁnal anchoring, the material from which the pace-
maker is made or the reaction induced in the
endocardium after a lead wire is introduced, which
might be different between patients.
Study limitations. The main limitation of this study
is its retrospective nature. However, this might also
be its strength, because it shows that the acquisition
of the 3D datasets necessary to analyze device-lead
position and relationship with surrounding
tricuspid valve leaﬂets does not entail any additional
complexity. Also it is possible that vena contracta
alone might not be sufﬁcient in estimating TR
severity in some patients with devices, because the
device lead itself might either interfere with the
visualization of the TR jet or, alternatively, result inCD, or CRT/Biventricular Device
Acquisition
maging to conﬁrm acquisition of the entire valve in orthogonal views.
m acquisition with 4-beat breath-hold to maximize frame rate.
nd position from right ventricular and right atrial perspectives to
the device-lead at the level of the annulus and leaﬂets.
me acquisition with 4-beat breath-hold. Maximize frame rate by
sing sector width to include only the right ventricle and atrium,
he acquisition in 3 to 4 image planes to conﬁrm acquisition of all
f the right ventricle, especially the lateral wall.
ramidal volume toward you and crop in a plane parallel to the valve
to the level of the valve leaﬂets to visualize the device-lead in
ce to the leaﬂets; the volume can also be cropped perpendicular
valve plane to follow the course of the device-lead or, alternatively
-lead course can also be followed in the multiplanar mode to assess
n of the device tip.
as in Table 1.
Mediratta et al. J A C C : C A R D I O V A S C U L A R I M A G I N G , V O L . 7 , N O . 4 , 2 0 1 4
Tricuspid Regurgitation by Implantable Devices A P R I L 2 0 1 4 : 3 3 7 – 4 7
346overestimated vena contracta measurement. Perhaps
3D color full-volume imaging might overcome this
obstacle (31), but it was not available in this retro-
spective study. Another potential limitation is the
lack of any gold standard with which to compare the
severity of TR. However, such a gold standard does
not exist, and the comparison between pre- and
post-implantation studies has clearly demonstrated
a relationship between right ventricle lead position
and TR severity. Furthermore, the clinical impact, if
any, of the TR seen in this study is not yet known.
Future directions. Awareness of an association be-
tween device-lead location and TR severity is
important, because re-positioning of the device-
lead at the time of implantation is typically the
simplest and safest opportunity to correct the
problem. Inﬂammatory changes are known to occur
at the site of device-lead placement as early as a few
days after lead implantation, with ﬁbrous tissue
formation weeks to months later. These changes
could potentially preclude repositioning of the
device-lead later (32). Although the morbidity and
mortality associated with device implantation is
reportedly low (0.6% to 1.1%) (33,34), the mor-
tality associated with tricuspid valve surgery is
considerably higher (6% to 10%) (35–37). Another
important consideration is that, in the presence of
signiﬁcant TR, the tricuspid valve annulus often
progressively dilates so that later lead repositioning
might be less beneﬁcial, because TR will likely
persist and worsen despite correction of lead
placement (38). Accordingly, a study that compares
3D TTE targeted guidance of device-lead place-
ment with non-guided lead placement (currentpractice) could be very informative. It is not known
whether targeted placement of the device-lead in
a commissure or in the middle of the valve means
that the lead will remain in that position. It has
been shown previously that, immediately after
device-lead implantation, TR is usually mild and
not clinically important (16), so that guiding
placement of device-leads on the basis of presence
or absence of TR on echocardiography or auscul-
tation is not likely to be useful. Accordingly, eval-
uation of TR severity and lead position before,
immediately after, and several months after device-
lead placement needs to be assessed in future
studies. It is possible that, if the device-lead was
placed in the intercommissural position, device-
related TR could be avoided altogether.
CONCLUS IONS
In this study, we found that device-lead position can
be assessed on 3D TTE in most patients. An
intercommissural or middle-of-the-annulus position
is desired to minimize device-related TR post-
implantation. Accordingly, this imaging modality
should be routinely used in this context. The results
of this study indirectly suggest that 3D TTE-
assisted device placement might lead to a reduc-
tion in lead-associated TR.
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